Phase 1 trial of Bi-shRNA STMN1 BIV in refractory cancer
M Barve, Z Wang, P Kumar, CM Jay, X Luo, C Bedell… - Molecular Therapy, 2015 - cell.com
… 1, 2) and RLM RACE (n = 1/1 patients analyzed cohort 3). In conclusion, bi-shRNA STMN1
BIV … target sequence-specific cleavage product confirmed bi-shRNA BIV mechanism of action. …
BIV … target sequence-specific cleavage product confirmed bi-shRNA BIV mechanism of action. …
In vivo Safety and Antitumor Efficacy of Bifunctional Small Hairpin RNAs Specific for the Human Stathmin 1 Oncoprotein
AP Phadke, CM Jay, Z Wang, S Chen, S Liu… - DNA and cell …, 2011 - liebertpub.com
… We have generated a novel bi-shRNA using the miR30 … The present study assessed the in
vivo efficacy of intratumoral (IT… BIV-encapsulated nucleic acids form flexible nanoplexes of 200…
vivo efficacy of intratumoral (IT… BIV-encapsulated nucleic acids form flexible nanoplexes of 200…
RNAi targeting STMN alleviates the resistance to taxol and collectively contributes to down regulate the malignancy of NSCLC cells in vitro and in vivo
D Long, T Yu, X Chen, Y Liao, X Lin - Cell Biology and Toxicology, 2018 - Springer
… Stathmin (STMN) plays a vital role in maintaining the … ranked tumor cells with obvious atypia
in tumor tissues with big … superficial advanced refractory cancer in phase I clinical trial and …
in tumor tissues with big … superficial advanced refractory cancer in phase I clinical trial and …
The microtubule network and cell death are regulated by an miR-34a/Stathmin 1/βIII-tubulin axis
NS Vetter, EA Kolb, CC Mills, VB Sampson - Molecular Cancer Research, 2017 - AACR
… STMN1) that cleaves STMN1 mRNA was evaluated in melanoma and osteosarcoma (39)
and in patients with superficial advanced refractory cancer (40) … In the current study, we have …
and in patients with superficial advanced refractory cancer (40) … In the current study, we have …
Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks
Z Yang, T Liu, X Ren, M Yang, C Tu, Z Li - Cell Cycle, 2022 - Taylor & Francis
… targeting, and miRNAs to silence STMN1 might be effective strategies to inhibit cell
division [Citation79–81]. Besides, a recent study showed that PAI-1 participates in the p53–miR-34a …
division [Citation79–81]. Besides, a recent study showed that PAI-1 participates in the p53–miR-34a …
Preclinical justification of pbi-shRNA EWS/FLI1 lipoplex (LPX) treatment for Ewing's sarcoma
DD Rao, C Jay, Z Wang, X Luo, P Kumar, H Eysenbach… - Molecular therapy, 2016 - cell.com
… Target protein and RNA knockdown of 85–92% was demonstrated in vitro in type 1
human Ewing's sarcoma tumor cell lines with the optimal bi-shRNA EWS/FLI1 plasmid. This …
human Ewing's sarcoma tumor cell lines with the optimal bi-shRNA EWS/FLI1 plasmid. This …
25 years of maturation: A systematic review of RNAi in the clinic
IJ Corydon, BK Fabian-Jessing, TS Jakobsen… - … Therapy-Nucleic Acids, 2023 - cell.com
… Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related …
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients …
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients …
[PDF][PDF] Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma
J Nemunaitis - 2016 - researchgate.net
… and will experience relapse or refractory progression [1, 21-24]. … Study e204 was designed
to follow body weight and tumor … bi-shRNA plasmid/LPX delivery vehicle targeting Stathmin 1 (…
to follow body weight and tumor … bi-shRNA plasmid/LPX delivery vehicle targeting Stathmin 1 (…
Improved nucleic acid therapy with advanced nanoscale biotechnology
Y Weng, Q Huang, C Li, Y Yang, X Wang, J Yu… - … Therapy-Nucleic Acids, 2020 - cell.com
… Meanwhile, more than 2,000 clinical trials of NA therapies are underway, and more NA
drugs are in the pipeline of biopharmaceutical companies. These data show us that the NA …
drugs are in the pipeline of biopharmaceutical companies. These data show us that the NA …
Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions
…, K Simon, K Němejcová, M Bártů, I Tichá… - Melanoma …, 2019 - journals.lww.com
… study has focused on the significance of stathmin expression in melanoma 6 . In this study,
the authors found that (a) stathmin … (b) the level of stathmin expression is negatively correlated …
the authors found that (a) stathmin … (b) the level of stathmin expression is negatively correlated …